Biosimilar adalimumab is a test of shared decision making in the NHS

Co-written by the National Rheumatoid Arthritis Society, National Ankylosing Spondylitis Society, RNIB, Birdshot Uveitis Society, Psoriasis Association and Crohn’s & Colitis UK

The entry of new biosimilars and the creation of an NHS ‘local market of treatment options’ will see significant numbers of patients switched from the originator product, Humira, to one of four biosimilar alternatives this year.

Adalimumab is one of several biological drugs used in the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, non-infectious posterior uveitis, Crohn’s and colitis.

While some patients will take this in their stride, for others the change will be met with feelings of apprehension. Read more Biosimilar adalimumab is a test of shared decision making in the NHS

Biologics and biosimilars – what are they?

By Jayne Lawrence, Head of Division of Pharmacy and Optometry, University of Manchester.

The Commissioning Framework for Biological Medicines announced recently by NHS England will both help guide improvements to developing better medicines for patients and provide a guide to ensuring the NHS gets best value for money from these innovative, exciting medicines.

What is a biologic?
Biological medicines have made many new, groundbreaking treatments possible, significantly improving the lives of many patients with long term conditions such as diabetes, arthritis, anaemia associated with chronic kidney failure, and types of cancer.

They are extremely expensive, in part due to the complexity of their production. For example, a course of a new immunotherapy drug typically costs more than £100,000 per patient per year. Furthermore, as biologicals currently comprise approximately 50% of all new drug approvals, it is likely that the high cost of new medicines is with us for the foreseeable future. Consequently, any way of reducing the cost of these important medicines is vital. Read more Biologics and biosimilars – what are they?